SAFETY AND TOLERABILITY OF LOSARTAN POTASSIUM, AND ANGIOTENSIN-II RECEPTOR ANTAGONIST, COMPARED WITH HYDROCHLOROTHIAZIDE, ATENOLOL, FELODIPINE ER, AND ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS FOR THE TREATMENT OF SYSTEMIC HYPERTENSION

This report presents data on the safety and tolerability of losartan potassium (losortan), a selective antagonist of the angiotensin II AT-1 receptor, in approximately 2,900 hypertensive patients treated in double-blind clinical trials. In these studies headache (14.1%), upper respiratory infection (6.5%), dizziness (4.1%), asthenia/fatigue (3.8%), and cough (3.1%) were the clinical adverse experiences most often reported in patients treated with losartan. These adverse experiences were also frequently reported in patients receiving placebo: 17.2%, 5.6%, 2.4%, 3.9%, and 2.6%, respectively. Dry cough as an adverse event was reported in 8.8% of patients treated with angiotensin-converting enzyme inhibitors, and in 3.1% and 2.6% of patients treated with losartan or placebo, respectively. Only dizziness was considered ''drug-related'' more often in losartan-treated (2.4%) than placebo-treated (1.3%) patients. In controlled clinical trials, losartan was better tolerated than other antihypertensive agents as determined by the incidence of patients reporting any drug-related adverse experiences. Rates of discontinuation due to clinical adverse experiences in patients who received losartan monotherapy or losartan + hydrochlorothiazide were 2.3% and 2.8%, respectively, compared with placebo (3.7%). No laboratory adverse experiences were unexpected or of clinical importance. First-dose hypotension rarely occurred with losartan or with losartan plus hydrochlorothiazide, and withdrawal effects such as rebound hypertension were not observed in clinical trials. There were no clinically important differences in the clinical or laboratory safety profiles in the demographic subgroups for age, gender, or race, In controlled clinical trials, losartan demonstrated on excellent tolerability profile.